1. Home
  2. BETR vs OMER Comparison

BETR vs OMER Comparison

Compare BETR & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Better Home & Finance Holding Company

BETR

Better Home & Finance Holding Company

HOLD

Current Price

$43.78

Market Cap

707.1M

Sector

Finance

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$9.42

Market Cap

628.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BETR
OMER
Founded
2014
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
707.1M
628.9M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
BETR
OMER
Price
$43.78
$9.42
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$27.50
AVG Volume (30 Days)
542.2K
1.7M
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$145,545,000.00
N/A
Revenue This Year
$53.90
N/A
Revenue Next Year
$74.16
N/A
P/E Ratio
N/A
N/A
Revenue Growth
43.79
N/A
52 Week Low
$7.71
$2.95
52 Week High
$94.06
$13.60

Technical Indicators

Market Signals
Indicator
BETR
OMER
Relative Strength Index (RSI) 37.42 63.77
Support Level $42.81 $8.04
Resistance Level $48.89 $10.41
Average True Range (ATR) 5.61 0.72
MACD -1.12 0.11
Stochastic Oscillator 11.42 78.06

Price Performance

Historical Comparison
BETR
OMER

About BETR Better Home & Finance Holding Company

Better Home & Finance Holding Co is a digital-first homeownership company whose services include mortgage, real estate, title, and homeowners insurance. The company has combined technology innovation and fresh thinking with a deep customer focus with the goal of revolutionizing the homeownership industry.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: